TTrialPathMatch Me to Trials
← Back to trials
RecruitingNeoplasms, Prostate

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Eligible age

18+ yrs

Accepts

Men

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Sponsor: GlaxoSmithKline

You may qualify if…

  • ✓ Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.
  • ✓ Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
  • ✓ Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
  • ✓ Progression on ADT and \>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant prostate cancer (CRPC) and received 1-2 prior taxane-based chemotherapy regimens. Participants should have received all approved standard-of-care therapies for which they are eligible, including biomarker directed therapy, in accordance with current clinical guidelines, unless a documented contraindication or another justified medical reason precluded their use.

You may not qualify if…

  • ✕ Pathological finding consistent with small cell, neuroendocrine carcinoma of the prostate, or any histology different from adenocarcinoma.
  • ✕ Impaired cardiac function or clinically significant cardiac disease.
  • ✕ Any significant medical condition, such as uncontrolled infection or clinically significant laboratory abnormality.
  • ✕ Prior therapy with Androgen receptor (AR) Degrader targeted therapy. Other protocol-defined inclusion/exclusion criteria apply.

Where it's recruiting

California

La Jolla · Los Angeles

Michigan

Grand Rapids

Pennsylvania

Philadelphia

Utah

West Valley City

Source: ClinicalTrials.gov · NCT07332455 · last updated 2026-11-09

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC · TrialPath